Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
04 avr. 2022 08h00 HE
|
Achilles Therapeutics PLC
- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS...
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
08 mars 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
01 mars 2022 07h02 HE
|
Achilles Therapeutics PLC
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and...
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
07 févr. 2022 07h30 HE
|
Achilles Therapeutics PLC
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Provides Business Update and Outlook for 2022
13 janv. 2022 07h30 HE
|
Achilles Therapeutics PLC
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
21 déc. 2021 08h00 HE
|
Achilles Therapeutics PLC
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
20 déc. 2021 08h00 HE
|
Achilles Therapeutics PLC
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
09 déc. 2021 07h00 HE
|
Achilles Therapeutics PLC
-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with...
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
12 nov. 2021 07h00 HE
|
Achilles Therapeutics PLC
LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
09 nov. 2021 08h00 HE
|
Achilles Therapeutics PLC
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...